Munich, Germany

Patrick Desmond Carroll

This inventor holds 1 USPTO granted patent. Top assignee: Regeneron Pharmaceuticals, Inc.. Active years: 2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Patrick Desmond Carroll. Retrieved from https://idiyas.com/inventor/patrick-desmond-carroll

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 14.0

ph-index = 1


Company Filing History:


Years Active: 2003

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Patrick Desmond Carroll: Innovator in Neurotrophic Factor Research

Introduction

Patrick Desmond Carroll is a notable inventor based in Munich, Germany. He has made significant contributions to the field of biotechnology, particularly in the area of neurotrophic factors. His work has implications for understanding and treating various neurological conditions.

Latest Patents

Patrick holds a patent for "DNA encoding human ciliary neurotrophic factor and method for producing the protein encoded thereby." This patent represents a crucial advancement in the production of proteins that can potentially aid in nerve regeneration and repair.

Career Highlights

Currently, Patrick is employed at Regeneron Pharmaceuticals, Inc., a leading biotechnology company known for its innovative therapies. His role at Regeneron allows him to work on cutting-edge research that aims to improve patient outcomes in neurology.

Collaborations

Throughout his career, Patrick has collaborated with esteemed colleagues, including Michael Sendtner and Kurt Stockli-Rippstein. These collaborations have fostered a productive research environment, leading to advancements in the understanding of neurotrophic factors.

Conclusion

Patrick Desmond Carroll's contributions to the field of neurotrophic factors and his innovative patent highlight his role as a key figure in biotechnology. His work continues to inspire advancements in neurological research and therapy.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…